CLVR (Clever Leaves Holdings) Debt-to-EBITDA : -0.11 (As of Dec. 2023)

What is Clever Leaves Holdings Debt-to-EBITDA?

Clever Leaves Holdings CLVR 12 Debt-to-EBITDA is -0.11 as of Dec. 2023. GuruFocus rates CLVR with a GF Score™ of 12/100.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clever Leaves Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.88 Mil. Clever Leaves Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.20 Mil. Clever Leaves Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $-18.36 Mil. Clever Leaves Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Clever Leaves Holdings's Debt-to-EBITDA or its related term are showing as below:

CLVR's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.66
* Ranked among companies with meaningful Debt-to-EBITDA only.

Clever Leaves Holdings (OTCPK:CLVR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Clever Leaves Holdings Debt-to-EBITDA Related Terms

Clever Leaves Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Clever Leaves Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clever Leaves Holdings Debt-to-EBITDA Chart

Clever Leaves Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.81

-1.90

-0.73

-0.10

-0.12

Clever Leaves Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial												-0.14	-0.19	-0.23	-0.09	-0.11

CLVR vs CNNC, CLSH, PRFX: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clever Leaves Holdings Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's Debt-to-EBITDA falls into.

Save Embed

12GF Score

Clever Leaves Holdings Inc CLVR

Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Clever Leaves Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Clever Leaves Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.884	+	1.203)	/	-16.835
	=	-0.12

Clever Leaves Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.884	+	1.203)	/	-18.364
	=	-0.11

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of -0.11 mean?

Clever Leaves Holdings (CLVR) has a Debt-to-EBITDA of -0.11 as of Dec. 2023. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clever Leaves Holdings.

Is Clever Leaves Holdings' Debt-to-EBITDA too high?

Clever Leaves Holdings' current Debt-to-EBITDA is -0.11. Overall, Clever Leaves Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Clever Leaves Holdings' Debt-to-EBITDA compare to CNNC and CLSH?

Clever Leaves Holdings' Debt-to-EBITDA of -0.11 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Drug Manufacturers company?

The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clever Leaves Holdings. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clever Leaves Holdings's current Debt-to-EBITDA is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Clever Leaves Holdings stock overvalued right now?

Clever Leaves Holdings (CLVR) has a current Debt-to-EBITDA of -0.11. The current Debt-to-EBITDA is -0.11. Clever Leaves Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For Clever Leaves Holdings (CLVR), the current Debt-to-EBITDA is -0.11 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clever Leaves Holdings Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies CNNC CLSH PRFX AGRX OWPC KOAN ABTI PLSH STEK INQD ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692

Address Bodega 19-B Parque Industrial Tibitoc P.H, Tocancipa, Cundinamarca, Bogota, COL

Website https://www.cleverleaves.com

Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments namely, the Cannabinoid segment which is comprised of the company's cultivation, extraction, and commercialization of cannabinoid products; and the Non-Cannabinoid operating segment which generates maximum revenue and is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.

12GF Score

Get the complete analysis for CLVR

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View CLVR Analysis

See Debt-to-EBITDA data for all stocks →